US 11,692,031 B2
Antibody constructs for CLDN18.2 and CD3
Christoph Dahlhoff, Munich (DE); Claudia Blümel, Munich (DE); Johannes Brozy, Munich (DE); Tobias Raum, Munich (DE); Elisabeth Nahrwold, Munich (DE); Tara Arvedson, Thousand Oaks, CA (US); Irwin Chen, Thousand Oaks, CA (US); Sandra Ross, Thousand Oaks, CA (US); and Julie Bailis, Thousand Oaks, CA (US)
Assigned to AMGEN RESEARCH (MUNICH) GMBH, Munich (DE); and AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN RESEARCH (MUNICH) GMBH, Munich (DE); and AMGEN INC., Thousand Oaks, CA (US)
Filed on Aug. 2, 2019, as Appl. No. 16/530,006.
Claims priority of provisional application 62/714,366, filed on Aug. 3, 2018.
Prior Publication US 2020/0055932 A1, Feb. 20, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 18 Claims
 
1. An antibody construct comprising a first domain which binds Claudin 18.2 (CLDN18.2), and a second domain which binds human CD3, wherein the first domain comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:
a) CDR-H1 as depicted in SEQ ID NO: 121, CDR-H2 as depicted in SEQ ID NO: 122, and CDR-H3 as depicted in SEQ ID NO: 123, CDR-L1 as depicted in SEQ ID NO: 124, CDR-L2 as depicted in SEQ ID NO: 125 and CDR-L3 as depicted in SEQ ID NO: 126; and
b) CDR-H1 as depicted in SEQ ID NO: 133, CDR-H2 as depicted in SEQ ID NO: 134, and CDR-H3 as depicted in SEQ ID NO: 135, and CDR-L1 as depicted in SEQ ID NO: 136, CDR-L2 as depicted in SEQ ID NO: 137 and CDR-L3 as depicted in SEQ ID NO: 138.